News
ACRS
1.645
+2.81%
0.045
Weekly Report: what happened at ACRS last week (0317-0321)?
Weekly Report · 7h ago
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeuticsto Overweight
Benzinga · 6d ago
Weekly Report: what happened at ACRS last week (0310-0314)?
Weekly Report · 03/17 09:12
Weekly Report: what happened at ACRS last week (0303-0307)?
Weekly Report · 03/10 09:12
Aclaris Therapeutics Price Target Announced at $15.00/Share by Scotiabank
Dow Jones · 03/07 22:24
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
TipRanks · 03/07 14:52
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Simply Wall St · 03/07 11:46
Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88%
Simply Wall St · 03/06 10:19
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
Barchart · 03/04 06:00
Weekly Report: what happened at ACRS last week (0224-0228)?
Weekly Report · 03/03 09:12
Aclaris Therapeutics: Strong Pipeline and Financial Stability Justify Buy Rating
TipRanks · 03/03 06:58
Aclaris Therapeutics Reports 2024 Financial Results
TipRanks · 02/28 04:45
Aclaris Therapeutics plans $300M mixed shelf offering
Seeking Alpha · 02/27 23:00
ACLARIS THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $300 MLN - SEC FILING
Reuters · 02/27 22:16
Aclaris Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 02/27 15:08
Aclaris Therapeutics Q4 2024 GAAP EPS $(1.01) Misses $(0.24) Estimate, Sales $9.21M Beat $2.11M Estimate
Benzinga · 02/27 12:17
Aclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c)
TipRanks · 02/27 12:11
ACLARIS THERAPEUTICS Q4 NET INCOME USD -96.552 MILLION VS. IBES ESTIMATE USD -22.4 MILLION
Reuters · 02/27 11:59
*Aclaris Therapeutics 4Q Rev $9.21M >ACRS
Dow Jones · 02/27 11:59
Press Release: Aclaris Therapeutics Reports -2-
Dow Jones · 02/27 11:59
More
Webull provides a variety of real-time ACRS stock news. You can receive the latest news about Aclaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).